Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
PMID: 22067667
2012
Journal of acquired immune deficiency syndromes (1999)
Abstract: More rilpivirine VFs had treatment-emergent nucleoside/nucleotide reverse transcriptase inhibitor RAMs than efavirenz VFs [68% (42 of 62) versus 32% (9 of 28), respectively], most commonly M184I and M184V.
Abstract: The frequent emergence of E138K, especially in combination with M184I, in rilpivirine VFs is a unique finding of these trials.
The impact of molecular manipulation in residue 114 of human immunodeficiency virus type-1 reverse transcriptase on dNTP substrate binding and viral replication.
Introduction: M184I, for example, is a transient 3TC resistant mutation, ultimately resulting in M184V.
Introduction: The M184I mutation was also found to change the tropism of an HIV-1 vector, preventing it from transducing human macrophages.
Introduction: The requirement of a certain volume in the active site of RT for an incoming dNTP would represent unique mechanism of substrate binding; unlike the mutation Q151N, that decreases the dNTP binding through a loss of interaction or M184I, which results in a steric clash with the incoming dNTP.
Introduction: We have shown that the M184I mutation also alters the binding of RT to dNTPs, raising the Kd to 56muM, which is similar to the Kd value of M
Short communication: Drug resistance mutations in the HIV type 1 protease and reverse transcriptase genes in antiretroviral-naive Vietnamese children.
PMID: 22260721
2012
AIDS research and human retroviruses
Abstract: In the RT gene, three major mutations were detected in six strains: the V75M mutation in one strain, the Y181C mutation in two strains, and the M184I mutation in three strains.
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Abstract: The most common UDS-detected DRM were NRTI in 18 subjects: M184V/I (11), TAMs(7) & K65R(4); PI DRMs were detected in 9 subjects: M46I/V(5), F53L(2), I50V(1), D30N(1), and N88S(1).
Discussion: Eleven of 24 patients had low or high level M184V/I variants; 7 had M184V/I at >=1% of the viral population, however only 4 of the 7 developed phenotypic resistance to FTC/3TC (all had M184V variant levels >95%).
Discussion: Interestingly, not all patients with M184V/I developed phenotypic resistance to F
HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis.
Introduction: Consistent with this observation, mechanistic analyses suggest that this mutation may compensate for the antagonism of TAMs by M184V/I and Y181C.
Introduction: For example, Yap et al reported that the N348I mutation is highly associated with TAMs, the lamivudine mutation M184V/I, and the non-nucleoside inhibitor resistance mutations K103N and Y181C/I.
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
PMID: 22371439
2012
The Journal of antimicrobial chemotherapy
Ab
Abstract: OBJECTIVES: To compare the frequency of the selection of the M184V/I resistance mutation in HIV-infected patients who experienced virological failure while receiving emtricitabine (FTC) or lamivudine (3TC), administered with tenofovir disoproxil fumarate (TDF) and either efavirenz (EFV) or a ritonavir-boosted protease inhibitor (PI; lopinavir or atazanavir).
Abstract: Proportions of patients harbouring the M184V/I mutation were 24% (n = 62) for those who received FTC + TDF + EFV versus 51% (n = 91) for 3TC + TDF + EFV (P < 0.0001; Fisher's exact test); proportions were 11% (n = 30) for FTC + TDF + ritonavir-boosted PI versus 22% (n = 37) for 3TC + TDF + ritonavir-boosted PI (P = 0.002; Fisher's exact test).
Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010.
Abstract: SDRMs were identified in 14/219 (6.4%) subjects; 8/14 were resistant to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs; T69D, L74V, V75M, M184V/I and K219R), 5/14 to non-nucleoside reverse transcriptase inhibitors (NNRTIs; K103N, V106M, Y181C, Y188C and G190A), 1/14 to both NRTIs and NNRTIs (D67N and Y181C) and none to PMID: 22585715
2012
Journal of medical virology
Abstract: The most common NRTI resistance mutation was M184V/I (74.1%).
HIV mutation literature information.
PMID: 
2012
Journal of acquired immune deficiency syndromes (1999)
Browser Board
Co-occurred Entities
Filtrator
ViMRT